Clinical Trial Search

Primary: Complete Control (no Signs of Emesis or Moderate to Severe Nausea and no Use of Rescue Medication) Rate From the Start of Radiotherapy Until 24 Hours After the Third…

Primary: Overall Complete Response Rate — 10; 10 percentage of participants

Primary: Safety and Tolerability of Palonosetron as Determined by the Number of Participants Who Experience Unacceptable Toxicity — 5 participants

Primary: Efficacy for the Prevention/Rescue of Radiation-induced Nausea and Vomiting. — 21; 4; 2; 0 Participants

Primary: Complete Response (CR) Rate as Measured by Antiemesis Tool (MAT) — 0.5717; 0.7368 proportion of participants — p=0.2734

Primary: Efficacy of the Aprepitant/Ramosetron/Dexamethasone Regimen in Terms of the Proportion of Patients With a Complete Response (CR) During the 120 Hour Following Initiation…

Primary: The Probability of Complete Responses Over Three Cycles of Chemotherapy After the Start of the MEC Administration — 0.810; 0.718 Probability of complete response — p=<0.05

Primary: Number of Participants With Acute Nausea and Vomiting — 101 Participants

Primary: Proportion of Patients Achieving Complete Control (CC) — 0.59; 0.55 proportion of patients

Primary: Average Nausea Defined as the Average [ MAXIMUM ] Nausea Rating Across 15 Assessment Points at Cycle 1 and 16 Assessment Points at Cycle 2 (Comparing Prochlorperazine or…

Primary: Percentage of Patients With Complete Control — 71.4; 76.0; 90.9 Percentage

Primary: No Emetic Episodes and No Rescue Medication — 72.7; 58.4 percentage of participants — p=<0.001

Primary: No Emetic Episodes and No Rescue Medication — 70.1; 61.9 percentage of participants — p=0.043

Primary: No Emetic Episodes and No Rescue Medication — 71.3; 61.6 percentage of particpants — p=<0.001

Primary: Percentage of Participants With Incidence of Vomiting/Retching From Day 1 Through End of Day 5 — 26.3 percentage of particpants

Primary: Percentage of Participants With Response Rate to Anti-Emetic Therapy Days 4-7 Each Chemotherapy Cycle — 49.8; 39.7 percentage of participants

Primary: Home Record: Severity of Delayed Nausea — 1.88; 1.65; 1.87; 1.68 units on a scale — p=0.718

Primary: Proportion of Patients With no Nausea — 73.8; 45.3; 42.4; 25.4 percentage of participants

Primary: Number of Patients With Gastrointestinal Toxicities (Grade 3 and 4 Nausea and Vomiting) Associated With Delivering Fluorouracil/Gemcitabine Hydrochloride-based…

Primary: Acute and Delayed Chemotherapy-Induced Nausea. The Self-reported Instruments Are Documented After the Chemotherapy Sessions and Collected on Study Visits 1, 2, and 3…

Primary: Number of Patients Who Reported No Vomiting — 324; 252 Participants — p=<0.01

Primary: Change in Nausea Numerical Rating Scale (NRS) Between Day 5 and Day 15 — -2.0; -2.3 score on a scale — p=0.98

Primary: Complete Response. — 47; 15 percentage of evaluable subjects

Primary: Complete Response (CR) Defined as no Emesis and no Rescue Therapy — 13 Participants

Primary: Number of Participants With no Emesis and no Rescue Therapy Within 5 Days of Receiving FOLFOX and FOLFIRI in the First Cycle of Chemotherapy. — 54 Participants

Primary: Mean Nausea Scores — 1; 9 units on a scale

Primary: Risk of Solitary Elective Volume Recurrence Following Elective Volume Reduction Using INRT — 11; 9; 3; 6 percentage of participants

Primary: Complete Acute Response — 4; 4; 3 Participants

Primary: Proportion of Participants Receiving HEC With Complete Response in Overall Phase — 20; 15 Participants — p=0.397

Primary: The Percentage of Participants With No Vomiting - Overall Stage — 77.2; 72.0 Percentage of Participants — p=0.191